Abstract
The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Current Vascular Pharmacology
Title:Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Volume: 12 Issue: 1
Author(s): Guido Grassi, Gino Seravalle, Gianmaria Brambilla, Francesca Cesana, Cristina Giannattasio and Giuseppe Mancia
Affiliation:
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Abstract: The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Export Options
About this article
Cite this article as:
Grassi Guido, Seravalle Gino, Brambilla Gianmaria, Cesana Francesca, Giannattasio Cristina and Mancia Giuseppe, Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990142
DOI https://dx.doi.org/10.2174/15701611113119990142 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir
Current Drug Discovery Technologies Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals The Profile of Angiogenic Factors in Vitreous Humor of the Patients with Proliferative Diabetic Retinopathy
Current Molecular Medicine Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan
Current Gene Therapy The beneficial effect of Cape gooseberry juice on carbon tetrachloride-induced neuronal damage
CNS & Neurological Disorders - Drug Targets Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension
Current Pharmaceutical Biotechnology Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Obesity: A New Pathology to Pay Attention to in Young People
Current Pharmaceutical Design Hyperandrogenism, Insulin Resistance and Hyperinsulinemia as Cardiovascular Risk Factors in Diabetes Mellitus
Current Diabetes Reviews Non-coding RNAs and Hypertension–Unveiling Unexpected Mechanisms of Hypertension by the Dark Matter of the Genome
Current Hypertension Reviews Interleukin-1β Plays a Role in the Activation of Peripheral Leukocytes after Blood-Brain Barrier Rupture in the Course of Subarachnoid Hemorrhage
Current Neurovascular Research Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer
Current Pharmaceutical Design Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery